Circio Secures Long-Term Funding with Oversubscribed Offering

Norwegian biotech Circio raises 250M NOK in oversubscribed placement, funding its circVec RNA platform into 2030 after breakthrough data showing up to 50-fold gene expression boost.

A wave of investor confidence has propelled Norwegian biotech firm Circio Holding into a strong financial position. The company has successfully closed a private placement raising 250 million NOK, with demand significantly outstripping the initial offer. This robust response has prompted the launch of a subsequent repair offering for existing shareholders, aiming to secure an additional 82.5 million NOK.

The private placement involved issuing approximately 23 million new shares at a subscription price of 10.80 NOK. This price point aligns with the current market valuation and sits notably above recent volume-weighted average prices. Combined, these capital injections provide Circio with a secured financial runway extending into 2030, allowing management to focus squarely on advancing its proprietary technology.

Central to the investment thesis are recent breakthroughs in Circio's circVec RNA platform. New experimental data demonstrates the technology's ability to boost gene expression dramatically—by up to 40-fold in heart tissue and an impressive 50-fold in specific tissues like the eye. These compelling results have already attracted significant industry attention, forming the basis for an ongoing feasibility study with one of the world's five largest pharmaceutical companies.

To accommodate the overwhelming investor interest and offer a second chance to existing shareholders, Circio is proceeding with a repair rights issue. This offering allows current investors to subscribe for up to 7.6 million additional shares at the same 10.80 NOK price. Trading in the shares on a "ex-subscription right" basis commenced this Wednesday. The offering is contingent on specific conditions, including the publication of a national prospectus and maintaining a stable share price above the subscription level, with the subscription period slated to begin in late April.

Demonstrating a strong commitment to the company's future, both the executive management and the board of directors have entered into a six-month lock-up period for their shares. The newly raised capital is earmarked primarily for accelerating the development and scaling of the circVec platform, which is designed for applications in gene and cell therapy.

The company's financial report as of March 31, 2026, shows a cash position of 42 million NOK. With the recent capital infusions, operational activities are fully funded for the coming years. Several key milestones are on the immediate horizon for investors, underscoring the busy period ahead.

On April 13, 2026, the full abstracts for the American Society of Gene and Cell Therapy (ASGCT) annual meeting will be released. This will be followed by the publication of Circio's 2025 annual report on April 15. The company will then take the global stage at the ASGCT conference in Boston from May 11 to 15, 2026.

Circio's presence at the Boston conference is particularly noteworthy. The company has been selected to deliver an oral presentation at the event, which is considered the world's premier conference for gene and cell therapy. This platform offers a significant opportunity to present detailed circVec data to a specialized international audience. Furthermore, Circio is expanding its research collaborations, partnering with institutions like the University of Texas and United Immunity to explore new applications for its platform in infectious diseases and novel cancer therapies.